The Pyo data above suggests the opposite to be true, though
As a result, coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively (Table 1)
HEXAGEN does not endorse human use of any compound
Thymosin Beta-4 Heritage: Parent compound is endogenous and well-characterized Clinical Trials: RegeneRx trials showed generally favorable safety in ophthalmic and cardiac applications Cancer Concerns: Theoretical concerns about cell migration and tumor potential
It's easier to use than growth hormone peptides, more targeted than comprehensive hormone optimization, and more effective than traditional fat burners
Mounajro can also be used for weight loss (off-label)